Radiotherapy of lymphomas.

Cancer Radiother

Centre François-Baclesse, BP 45026, 14076 Caen cedex 5, France; Épidémiologie des radiations, CESP, Inserm U1018, hôpital Paul-Brousse, 16, avenue Paul-Vaillant-Couturier, 94807 Villejuif cedex, France; Service d'oncologie pédiatrique, CHU d'Angers, 4, rue Larrey, 49100 Angers, France.

Published: February 2022

Radiotherapy for Hodgkin lymphomas has evolved a lot over time, but still plays an important role, almost always in addition to chemotherapy, for the management of the early stages. The major objective is to preserve the quality of life of patients who will be cured from this disease in the vast majority of cases. Also, the personalization of the indications for the purpose of de-escalating toxicity is very refined and is essentially based on the pre- and pertherapeutic assessment by FDG-PET. The indications for radiotherapy are more limited for non-Hodgkin lymphomas, but the same principles are found, regardless of the histological type. We present the update of the recommendations of the French society of oncological radiotherapy for radiotherapy of lymphomas, which remains a very evolving field in terms of therapeutic strategy and evaluation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canrad.2021.11.007DOI Listing

Publication Analysis

Top Keywords

radiotherapy lymphomas
8
radiotherapy
5
lymphomas radiotherapy
4
radiotherapy hodgkin
4
hodgkin lymphomas
4
lymphomas evolved
4
evolved lot
4
lot time
4
time plays
4
plays role
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!